Research updates
Vall d’Hebron receives funding from ISCIII for LAMA2 research project
We are excited to share that the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, has received funding from the…
Research updates
-
![]()
Research updates
-
![]()
News
A look back on a conference to shape LAMA2 clinical care guidelines
We are delighted to reflect on the success of the ENMC conference, initiated by Voor Sara and Cure CMD. Together,…
-
![]()
Research updates
Spain’s ongoing LAMA2-CMD natural history study
In 2022, a natural history study was initiated with LAMA2-CMD patients at Barcelona’s Vall d’Hebron Institute of Research. Natural history…
-
![]()
News
One step closer: FDA grants Rare Pediatric Disease designation to Modalis Therapeutics’ MDL-101 gene therapy
Modalis Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to…
-
![]()
News
Workshop to establish subtype-specific care recommendations for LAMA2-CMD
We are thrilled to announce a new clinical workshop focused on establishing subtype-specific care recommendations for LAMA2-RD, and using this experience as a prototype to develop recommendations for…
-
![]()
News
Dr. Voermans secures funding for extension of LAMA2-CMD natural history study
In 2022, Dr. Nicol Voermans and her team at Radboud UMC, Netherlands, launched the LASTSTRONG natural history study. With new…
The driving forces behind Lama2.com
Bekijk alle partners
